



**BioProcess  
International**  
by informa ...

## **BioProcess International Theater**

**Day One AM: Global Supply Chain and CDMO  
Capacity**

**Day One PM: Global Access & Affordability of  
Biologics**

**Day Two AM: Cells and Upstream Processing**

**Day Two PM: Recovery, Purification and Viral  
Safety**

**San Diego Convention Center, June 22-25, BC,  
San Diego, CA**

<https://convention.bio.org/>

2026 Tracks:

- **Day One AM: Global Supply Chain and CDMO Capacity**
- **Day One PM: Global Access & Affordability of Biologics**
- **Day Two AM: Cells and Upstream Processing**
- **Day Two PM: Recovery, Purification and Viral Safety**
- All speakers marked with \* are subject to final confirmation

**Want To Showcase Your Technology, Service and Data at  
BIO as part of the BPI Theater?**

**For Sponsorship and Exhibition Opportunities:**

**Alexander Zenenos**

Business Development Director | Life Sciences | Informa Connect

Work number: +442080522049

[Alexander.Zenonos2@informa.com](mailto:Alexander.Zenonos2@informa.com) [www.bioprocessintl.com](http://www.bioprocessintl.com) [www.informaconnect.com](http://www.informaconnect.com)

# Day One

San Diego Convention Centre, San Diego, CA

Tuesday 23rd June, 2026

Day 1

## Global Supply Chain and CDMO Capacity

**Theme: Building resilient biologic supply chains, global capacity constraints, expansion in Asia and Eastern Europe, long term partnerships versus transactional outsourcing, technology innovation among CDMOs, data integrity.**

*Welcome Session: BioProcess Insider, Hosted by BPI Magazine*

### Industry Case Study: Readyng Operations for Launch or Expansion

- Contracting and Pricing
- Demand Forecasting
- Gross-to-Net
- Pre-/Post- Deal Analysis
- Accruals Management
- Revenue Management

*Speaker: Brian Barbash, Partner, Pharosity Consulting*

This session will cover a series of 3 x 20-minute presentations involving steps to optimise and achieve global access and reduce costs. Current needs by the industry that need to be met are:

- Strategies for promoting competition and biosimilar uptake
- Innovative approaches to health technology assessment (HTA)
- Lean manufacturing and process optimization
- Technology transfer and local production in LMICs
- Strategies for managing supply chain risks and disruptions
- Leveraging digital technologies for cost reduction

BioProcess Insider Focus – 3 x 10-minute presentations followed by a Panel Discussion with all presenters.  
*CDMO Capacity and Client Partnership Panel*

- How do you ensure your capacity planning aligns with actual client requirements rather than assumptions?
- How do you balance multiple clients competing for the same capacity windows?
- How do you build flexibility into capacity planning when client needs can change rapidly?
- How do you maintain quality standards while maximizing capacity utilization?
- How do you communicate capacity constraints to clients while maintaining strong relationships?
- What contingency plans do you have for equipment failures, product issues, or unexpected downtime?
- What makes a CDMO-client relationship successful over the long term?

*Speakers: A Representative from Enzene*



10  
minutes

*Insider Interview: Enzene*



10  
minutes

*Insider Interview: Rentschler Biopharma SE*



*Insider Interviews: 2 x 10-minute interviews. Key Opinion Leaders will give their take on hot topics facing the industry at this time. This could include:*

- How to focus on niche therapies and smaller patient populations?

- How to reduce environmental footprint across the value chain?
- How to adapt portfolio strategy to the new IRA landscape?
- How to leverage venture capital and strategic partnerships?
- How to optimize R&D spending and improve efficiency?
- What are the market consolidation, emerging technologies, and financial pressures driving dealmaking?
- How to leverage CDMO expertise to optimize processes and reduce costs?
- New initiatives in the industry and by individual companies
- Biggest challenge overcome in 2025

### Global Access and Affordability of Biologics

**Theme: Rising R & D and manufacturing costs, innovation versus affordability, Global biosimilar adoption, IP and patents, regional product hubs for access, tech transfer, cold-chain logistics, pricing models**

#### Case Study From Rezon Bio

Speaker: A Representative from Rezon Bio



This session will cover a series of 2 x 20-minute presentations involving steps to optimise and achieve global access and reduce costs. Current needs by the industry that need to be met are:

- Strategies for promoting competition and biosimilar uptake
- Innovative approaches to health technology assessment (HTA)
- Lean manufacturing and process optimization
- Technology transfer and local production in LMICs
- Strategies for managing supply chain risks and disruptions
- Leveraging digital technologies for cost reduction

#### PANEL DISCUSSION: Biologics Breakthrough: Cutting Costs While Expanding Global Reach

What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations?

How are you balancing the capital investment required for continuous manufacturing against the long-term cost savings and efficiency gains?

Which specific single-use technologies have provided the best combination of cost reduction and manufacturing flexibility in your experience?

What strategies have most effectively reduced cold chain costs while ensuring product integrity during global distribution?

How are you leveraging data analytics to identify and eliminate hidden cost drivers in your biologics manufacturing and distribution networks?

What approaches have successfully reduced regulatory compliance costs without compromising quality or patient safety?

How do you optimize the trade-off between centralized manufacturing efficiency and the cost benefits of regional production closer to end markets?

Which emerging technologies show the most promise for dramatically reducing per-unit production costs of biologics in the next five years?

What innovative pricing or distribution models are you implementing to expand patient access in price-sensitive markets?

How are you measuring and balancing the sometimes competing priorities of cost reduction, manufacturing efficiency, and broader global distribution?

End of Day 1

## Day Two

Wednesday 24<sup>th</sup> June, 2026

Day 2

### Cells and Upstream Processing

*Theme: Clone selection and screening, stable cell line generation, transfection technologies, custom media development, Bioreactors, Upstream automation and PAT*

*Welcome Session: BioProcess Insider, Hosted by BPI Magazine*

#### **Industry Keynote: Application of QbD in Cell Therapy Development**

*Speaker: Lee Smith, Principal Consultant, Director, Greyrigge*

This session will cover a series of 3 x 20-minute presentations involving bioprocessing of the future. The aims of these.....

- Single-use vs. stainless steel considerations
- Perfusion and fed-batch optimization
- Scale-down models and predictive capabilities
- Real-time monitoring and control systems
- High-producing cell line generation
- Genetic stability and characterization
- Media optimization and chemically defined formulations
- Clone selection and banking strategies

BioProcess Insider Focus – 3 x 10-minute presentations followed by a Panel Discussion with all presenters.  
Suggested Topic: Optimizing Upstream Bioprocessing and Cell Line Development: From Innovation to Implementation  
A Panel Discussion on Technologies, Strategies, and Services Driving Efficiency in Biomanufacturing

*BioProcess Insider Interviews: 4 x 10-minute interviews. Key Opinion Leaders will give their take on hot topics facing the industry at this time. This could include:*

- How do you see AI/ML changing upstream processing in the next 5 years?
- What's your perspective on the sustainability challenges in biomanufacturing?
- How would you approach implementing continuous manufacturing for a new product?
- What are the key considerations for cell and gene therapy manufacturing scale-up?
- How do you balance innovation with regulatory compliance?
- What role should digital twins play in bioprocess development?
- How do you evaluate the business case for new technologies?
- What are the biggest supply chain risks in upstream processing today?

### Recovery, Purification and Viral Safety

*Theme: Harvest and Clarification, Capture and Initial Purification, Polishing and Impurity Removal, Filtration, Viral Clearance, Formulation, PAT*

#### **Overview of the latest analytics innovations**

*Speaker: Kevin Zen, CMC Technical Operations, Opthea*

This session will cover a series of 3 x 20-minute presentations involving steps to successful develop and manufacture complex biologics. Current needs by the industry that need to be met are:

- Digital Transformation and AI/ML Integration

- Continuous Chromatography Platforms
- Complex Therapeutic Modalities Purification
- Sustainability and Green Processing

Panel Discussion: Optimizing Downstream Processing: Innovations, Efficiencies, and Future Directions

Panel Description:

As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to streamline and optimize downstream processing (DSP) has never been greater. This panel brings together industry leaders and technical experts to discuss the latest innovations, strategic approaches, and critical pain points in downstream bioprocessing for both traditional biologics and advanced therapies.

From advanced purification technologies such as chromatography, membrane filtration, tangential flow filtration (TFF), ultracentrifugation, and affinity-based methods tailored for proteins, viral vectors, and nucleic acids, to automation, real-time analytics, and platform strategies for scalable manufacturing, our panellists will explore how to improve yield, consistency, and scalability while controlling cost and ensuring product quality.

**End of Theatre**

---

## Want some more information?

**For Sponsorship and Exhibition Opportunities:**

**Alexander Zenenos**

Business Development Director | Life Sciences | Informa Connect

*Work number: +442080522049*

[Alexander.Zenonos2@informa.com](mailto:Alexander.Zenonos2@informa.com) [www.bioprocessintl.com](http://www.bioprocessintl.com) [www.informaconnect.com](http://www.informaconnect.com)

**For Agenda and Speaking Enquiries:**

**Eden Turner**

Portfolio Manager | Pharma and Life Sciences | Informa Connect

*Work number: +44 (0)20 8052 0622*

[eden.turner@informa.com](mailto:eden.turner@informa.com) [www.informaconnect.com](http://www.informaconnect.com) [BioProcess International](http://BioProcess International)